Erlotinib, in combination with bevacizumab for the second line treatment of non-squamous advanced or metastatic non-small-cell lung cancer after previous platinum containing chemotherapy
Status Suspended
Decision Selected
Process TA
Referral date 01 November 2008

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Assessment Group / Evidence Review Group: Liverpool Reviews and Implementation Group
Communications manager: Alice Law
Executive Lead: Peter Littlejohns
Technical Lead: Sally Gallaugher


Key events during the development of the guidance:

Date Update
2 July 2009 Appraisal suspended.
6 July 2009

The manufacturer of erlotinib has advised us that regulatory approval for this technology is not being sought. The Institute has therefore decided to remove this appraisal from its current work programme.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes

For further information on our processes and methods, please see our CHTE processes and methods manual